Compare Realty Income Corp (O) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Realty Income Corp trades at $55.64 (market cap $52.03B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Realty Income Corp is far larger — about 6.9× Spyre Therapeutics Inc. Common Stock's market cap, and Realty Income Corp pays a 5.92% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 128 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| O | SYRE | |
|---|---|---|
Market Cap | $52.03B | $7.52B |
Volume | 16,838,213 | 1,441,031 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $108.92 |
52-Week Low | $53.35 | $22.18 |
Typical Hold Time | 128 Days | 0 Days |
Enterprise Value | $82.66B | $6.52B |
Dividend Yield | 5.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $54.99, up 0.53% on the day, but remains in a bearish technical trend amid recent earnings misses. The stock's valuation appears elevated with a P/E of 40.14 and P/S of 8.53, though profitability is strong with a 92.56% gross margin. Recent news highlights the stock's decline as Treasury yields rise, pressuring REIT valuations, while the company maintains a robust dividend history with consistent monthly payouts.
Outlook: Moderate upside to the $64.16 consensus price target exists, supported by solid fundamentals and high analyst buy ratings, but risks include interest rate sensitivity, debt growth, and competitive pressures. The stock offers income appeal but faces near-term headwinds from macroeconomic conditions.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
